Status:
TERMINATED
Neurofilaments for NEDA Assessing in MS
Lead Sponsor:
Queen Mary University of London
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Brief Summary
Goal is to evaluate the achievement of biological NEDA as demonstrated by a drop in neurofilament levels in MS patients commencing Alemtuzumab therapy as part of their MS management.
Detailed Description
Primary 1. To evaluate the achievement of NEDA using blood and CSF neurofilaments in Alemtuzumab treated patients. Secondary 2. To assess prognosis at the end of the study based on neurofilament ...
Eligibility Criteria
Inclusion
- Diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS).
- Age 18-55 years.
- EDSS score between 0-5.5.
- Commencing Alemtuzumab therapy at Neurology Infusion and Planned Investigation Unit, The Royal London Hospital, Ward 11D
Exclusion
- A diagnosis of Secondary Progressive MS (SPMS) or other forms of progressive MS.
- Those unable to comply with study requirement
Key Trial Info
Start Date :
August 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 28 2022
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT03250169
Start Date
August 1 2017
End Date
January 28 2022
Last Update
February 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary University of London
London, England, United Kingdom, E1 2AT